A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs JNJ 63709178 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Janssen Research & Development
- 20 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 29 Oct 2020.
- 20 Jul 2017 Planned End Date changed from 27 Oct 2020 to 1 Oct 2020.
- 10 Jun 2017 Biomarkers information updated